Evidence map›Paper›PMID 25217253›Full record

ArticleMolecular pain2014

Epigenetic regulation of spinal cord gene expression controls opioid-induced hyperalgesia.

De-Yong Liang, Yuan Sun, Xiao-You Shi, Peyman Sahbaie, J David Clark

Open access · goldAbstract read
In one paragraph

Article in Molecular pain, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. A review of the kappa opioid receptor system in opioid use.Neuroscience and biobehavioral reviews · 2024
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Sex differences in neural mechanisms mediating reward and addiction.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Review
  14. Article
  15. The NAJournal of molecular medicine (Berlin, Germany) · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

De-Yong Liang
Yuan Sun
Xiao-You Shi
Peyman SahbaieDepartment of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305, USA. psahbaie@stanford.edu.
J David Clark
Stanford University · USVA Palo Alto Health Care System · US

Funding

Genetics and Gene X Environment Interactions during Opioid AdministrationI01BX000881 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI CLARK, DAVID J. · 2011 to 2019
–
BLRD VA I01 BX000881
6 · The paper itself

Abstract

backgroundThe long term use of opioids for the treatment of pain leads to a group of maladaptations which includes opioid-induced hyperalgesia (OIH). OIH typically resolves within few days after cessation of morphine treatment in mice but is prolonged for weeks if histone deacetylase (HDAC) activity is inhibited during opioid treatment. The present work seeks to identify gene targets supporting the epigenetic effects responsible for OIH prolongation.

resultsMice were treated with morphine according to an ascending dose protocol. Some mice also received the selective HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) additionally. Chronic morphine treatment with simultaneous HDAC inhibition enhanced OIH, and several spinal cord genes were up-regulated. The expression of Bdnf (Brain-derived neurotrophic factor) and Pdyn (Prodynorphin) were most closely related to the observed behavioral changes. ChIP (Chromatin immuoprecipation) assays demonstrated that promoter regions of Pdyn and Bdnf were strongly associated with aceH3K9 (Acetylated histone H3 Lysine9) after morphine and SAHA treatment. Furthermore, morphine treatment caused an increase in spinal BDNF and dynorphin levels, and these levels were further increased in SAHA treated mice. The selective TrkB (tropomyosin-receptor-kinase) antagonist ANA-12 reduced OIH when given one or seven days after cessation of morphine. Treatment with the selective kappa opioid receptor antagonist nor-BNI also reduced established OIH. The co-administration of either receptor antagonist agent daily with morphine resulted in attenuation of hyperalgesia present one day after cessation of treatment. Additionally, repeated morphine exposure induced a rise in BDNF expression that was associated with an increased number of BDNF+ cells in the spinal cord dorsal horn, showing strong co-localization with aceH3K9 in neuronal cells. Lastly, spinal application of low dose BDNF or Dynorphin A after resolution of OIH produced mechanical hypersensitivity, with no effect in controls.

conclusionsThe present study identified two genes whose expression is regulated by epigenetic mechanisms during morphine exposure. Treatments aimed at preventing the acetylation of histones or blocking BDNF and dynorphin signaling may reduce OIH and improve long-term pain using opioids.

Indexed as

Analgesics, OpioidAnimalsAntineoplastic AgentsAzepinesBenzamidesBrain-Derived Neurotrophic FactorDisease Models, AnimalDynorphinsEpigenesis, GeneticGene Expression RegulationHydroxamic AcidsHyperalgesiaMaleMiceMice, Inbred C57BLMorphineANA 12 compoundAnalgesics, OpioidAntineoplastic AgentsAzepinesBenzamidesBrain-Derived Neurotrophic FactorDynorphinsHydroxamic AcidsMorphineNaltrexoneNarcotic AntagonistsnorbinaltorphimineVorinostat

Identifiers

PMID25217253
PMCPMC4171542
OpenAlexW1997053977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.